Administration of eptinezumab (humanized anti-CGRP monoclonal antibody) intravenously (IV) every 12 weeks was found to be safe with clinically effective results in cases of episodic or chronic migrane, as per a integrated analysis issued in The Journal of Headache and Pain.

To examine the safety and tolerability of eptinezumab, Timothy R. Smith et al. recruited 2867 patients with migraine.

Out of the total eptinezumab was administered in 2076 patients (4797 infusions) and placebo in 791 patients (1675 infusions). Overall adverse events (AEs) not related to the eptinezumab has been presented in the following table :

About ≥2% of patients in the eptinezumab 300-mg group had nasopharyngitis and with a frequency of minimum of 2 percentage points more as compared to placebo group; nevertheless, in most patients its occurrence was considered linked with study drug. While none of the patients in placebo group had hypersensitivity, about 1.1% patients reported as having hypersensitivity in eptinezumab group. Most hypersensitivity reactions were not severe and managed with usual medical therapy or observation without therapy, typically in a day.